The purpose of this study is to see if it is safe to give GENEVAX-HIV, a new HIV vaccine, to
HIV-negative volunteers. This study will also look at how this vaccine affects the immune
system of these volunteers.
In this open-label study, volunteers are given an intramuscular injection of GENEVAX-HIV
vaccine using the Biojector 2000. Safety measures and immune response are assessed
You may be eligible for this study if you:
- Are 18 - 60 years old.
- Are HIV-negative and in good health.
- Are able to understand how infections such as HIV are spread.
- Agree to use effective methods of birth control during the study.
You will not be eligible for this study if you:
- Have hepatitis B or C.
- Have any condition that may prevent you from completing the study.
- Are allergic to bupivacaine, vaccines, or certain local anesthetics.
- Have taken certain medications or have received certain therapies that may affect
your immune system.
- Have an immune system disorder or have received therapy for an immune system
- Have been exposed to HIV within 6 months prior to study entry.
- Have received an experimental HIV vaccine or any other experimental treatment within
30 days prior to study entry.
- Have received blood transfusions within 6 months prior to study entry.
- Abuse alcohol or drugs or have an uncontrolled psychiatric disorder.
- Are pregnant or breast-feeding.